Skip to main content
. 2019 Dec 19;10:5795. doi: 10.1038/s41467-019-13616-1

Fig. 6. Oral treatment with UCB-9260 inhibits TNF-driven functional effects in vivo.

Fig. 6

a UCB-9260 (10–300 mg/kg po, PBS n = 4; vehicle n = 8; UCB-9260 10, 30 and 300 mg/kg n = 6 and 100 mg/kg n = 8; CDP571 n = 5 mice) dose-dependently inhibits human and (b) mouse TNF-induced neutrophil recruitment to the peritoneal compartment in mice (PBS n = 3; vehicle n = 8; UCB-9260 10 mg/kg n = 7, 30 mg/kg n = 6, 100 and 300 mg/kg n = 8; CDP571 n = 5 mice). c UCB-9260 (150 mg/kg po bid) significantly reduces arthritis clinical score in the CAIA model (vehicle n = 8; UCB-9260 n = 8 and AB501 n = 6 mice). Mean data ± standard error is shown. *p < 0.05, **p < 0.01, ***p < 0.001 determined using one-way ANOVA with Dunnett’s multiple comparison test. Exposure of UCB-9260 can be found in Supplementary Tables 4–6. Source data are provided as a Source Data file.